FDA Accepts Sarepta's sNDAs for Amondys 45 and Vyondys 53, Sets Feb 2027 PDUFA Date
SRPT sits 66% above its 52-week low of $10.415.
Summary
Sarepta Therapeutics announced the FDA's acceptance of Supplemental New Drug Applications (sNDAs) for its Duchenne muscular dystrophy drugs, Amondys 45 and Vyondys 53. This is a positive regulatory development, indicating the FDA will proceed with reviewing the applications. The agency has set a PDUFA target action date of February 28, 2027, for a decision, providing a clear timeline for potential label expansions or other product enhancements.
At the time of this announcement, SRPT was trading at $17.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $10.42 to $25.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.